Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Puma Biotechnology, Inc.NASDAQ: PBYI

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense grows, but more slowly than its trailing trend

Q1 FY2026 income tax expense of $326K rose 11.3% year over year, behind the +177.1% change in trailing-twelve-month income tax expense. Sequentially, it fell 91.1% from the prior quarter. Over 3 fiscal years it compounded at +117.3% a year.

Context

  • Income tax expense amounted to 2.0% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +11.3% toward the trailing-twelve-month pace of +177.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$326K-91.1% QoQ
Last fiscal yearDec 2025
$4.67M+175.6% YoY
LTMMar 2026
$4.7M+177.1% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.3%——
1 year+175.6%——
3-year CAGR+117.3%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
4.67M USD
Year-over-year change
+175.6%
4-year CAGR
+94.9%

Income Tax Expense vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +177.1% is the highest of 6, against a peer median of -100.0%.
  • Income tax expense amounts to 2.1% of revenue for PBYI, versus a peer median of 0.0%.
PBYI Competitors
Income Tax Expense for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PBYIPuma Biotechnology, Inc.LTM Mar 2026$4.7M USD+177.1%+117.3%2.1%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$170.54K CAD+63.3%+18.9%—
NUVBNuvation Bio Inc.LTM Jun 2026$0 USD——0.0%
VSTMVerastem, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$0 USD———
CRDFCardiff Oncology, Inc.LTM Mar 2026$0 USD——0.0%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY+100.0%——
TNGXTango Therapeutics, Inc.LTM Sep 2026-$53K USD-149.1%-58.0%—
MGNXMacroGenics, Inc.LTM Mar 2026-$672K USD-171.2%—0.4%
Peer median (excluding PBYI) —-100.0%-19.6%0.0%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue253.16M228.03M235.64M230.47M228.37M
Cost of Revenue63.7M55.09M62.68M64.4M58.16M
Gross Profit189.45M172.94M172.96M166.06M170.21M
Gross Margin74.8%75.8%73.4%72.1%74.5%
Research & Development71.87M52.24M50.38M54.94M62.07M
Selling, General & Admin116.29M89.98M89.31M80.16M71.21M
Operating Expenses188.16M149.22M140.32M135.1M132.92M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
EBITDA(4.69M)21.89M47.52M48.08M53.34M
EBITDA Margin-1.9%9.6%20.2%20.9%23.4%
Operating Income1.29M23.72M32.64M30.97M37.3M
Operating Margin0.5%10.4%13.9%13.4%16.3%
Interest Income160K813K2.61M4.72M4.08M
Interest Expense12.81M11.59M13.33M12.45M6.62M
Other Income / Expenses(30.09M)(23.26M)(9.97M)(6.87M)(1.52M)
Income Before Tax(28.8M)457K22.67M24.1M35.78M
Pre-Tax Margin-11.4%0.2%9.6%10.5%15.7%
Income Tax Expense324K455K1.08M(6.18M)4.67M
Net Income(29.13M)2K21.59M30.28M31.11M
Net Margin-11.5%0.0%9.2%13.1%13.6%
EPS (Basic)(0.72)0.020.460.620.62
EPS (Diluted)(0.72)0.020.450.620.61
Weighted Avg Shares40.64M44.67M47.13M48.65M50.01M
Weighted Avg Shares (Diluted)40.64M44.93M47.55M49.1M50.65M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.